U.S. markets open in 6 hours 37 minutes
  • S&P Futures

    4,130.25
    +2.50 (+0.06%)
     
  • Dow Futures

    33,717.00
    +8.00 (+0.02%)
     
  • Nasdaq Futures

    13,749.50
    -0.75 (-0.01%)
     
  • Russell 2000 Futures

    2,239.50
    +11.20 (+0.50%)
     
  • Crude Oil

    61.89
    +0.46 (+0.75%)
     
  • Gold

    1,784.00
    +2.00 (+0.11%)
     
  • Silver

    26.12
    -0.06 (-0.21%)
     
  • EUR/USD

    1.2035
    +0.0017 (+0.14%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    18.71
    +1.21 (+6.91%)
     
  • GBP/USD

    1.3862
    +0.0019 (+0.14%)
     
  • USD/JPY

    107.8890
    -0.0710 (-0.07%)
     
  • BTC-USD

    48,685.51
    -5,810.33 (-10.66%)
     
  • CMC Crypto 200

    1,100.84
    -142.21 (-11.44%)
     
  • FTSE 100

    6,938.24
    +42.95 (+0.62%)
     
  • Nikkei 225

    29,020.63
    -167.54 (-0.57%)
     

Geyser Brands Inc. Awarded Health Canada NPN Number for Its Eczema (Psoriasis) Topical Cream

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

VANCOUVER , May 26, 2020 /CNW/ - Geyser Brands Inc. (GYSR.V)("Geyser Brands" or the "Company") is pleased to announce the receipt of their Natural Product Number (NPN) from Health Canada for their hemp-based topical Eczema (Psoriasis) cream. Through the issuance of the NPN, products that carry an NPN have been assessed by Health Canada and found to be safe, effective and of high quality under their recommended conditions of use. The new product has proved to be very effective in the treatment of both Psoriasis & Eczema.

Geyser Brands Inc. (CNW Group/Geyser Brands Inc.)
Geyser Brands Inc. (CNW Group/Geyser Brands Inc.)

Geyser Brands' Solace subsidiary is authorized to market and sell their Eczema cream as a natural health product through the Apothecary Naturals and SToND Naturals line of products.

Solace will also be offering a version of this product through the brand Apothecary Labs in the regulated Cannabis market. Apothecary Labs will be using the same base product and adding CBD & THC.

According to a report Aug 2019 by Grand View Research, Inc., the global atopic dermatitis drugs market size is expected to reach USD 6.41 billion by 2022.

With distribution through traditional retailers and direct-to-consumer, products are expected to hit shelves in June, 2020. Regulated cannabis versions are expected to be available at government licensed dispensaries by August 2020 .

The Solace subsidiary carries the Apothecary line of brands including:

"Receiving our NPN supports our vision to develop and build brands based on trust and credibility in an emerging but heavily regulated industry. Our continued focus on natural, healthy ingredients along with world-class formulations has been recognized with this NPN and we look forward to rolling these out in Canada as a first step in building a global presence", stated Geyser Brands Chairman, Brad Kersch .

About Geyser Brands

Geyser Brands Inc. develops consumer product brands in the health and wellness sector that use hemp and CBD as a value-added ingredient. These involve next-generation formulas that focus on the mix of cannabinoids for specific conditions such as insomnia, anxiety and pain.

Proprietary delivery technologies include all natural nano-technology, slow-release mechanisms and non-molecule degrading baking processes. In anticipation of coming edibles legislation, and with its Health Canada approved Licensed Production Facility, Geyser Brands has 15,000 square feet in two GMP facilities in Vancouver, BC .

For more information, visit Geyser Brands' website at www.geyserbrands.com.

On Behalf of the Board of Directors

" Andreas Thatcher "
____________________________________
Andreas Thatcher
Director and CEO
info@geyserbrands.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release contains forwardlooking statements and forwardlooking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forwardlooking statements or information. Forwardlooking statements and information are often, but not always, identified by the use of words such as "appear", "seek", "anticipate", "plan", "continue", "estimate", "approximate", "expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe", "would" and similar expressions.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forwardlooking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with the marijuana industry in general such as operational risks in growing; competition; incorrect assessment of the value and potential benefits of various transactions; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and government regulations. Accordingly, readers should not place undue reliance on the forwardlooking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information relating to Geyser is available at www.sedar.com.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Geyser Brands Inc.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2020/26/c2629.html